Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
A qualitative or semi-quantitative immunoassay for tumor antigen, such as bladder tumor antigen, is performed to detect the presence of specific tumor markers in the body. Tumor antigens are substances produced by cancer cells or by the body in response to cancer, and their presence can indicate the potential existence of a malignant neoplasm. In this context, the bladder tumor antigen (BTA) is specifically assessed using a latex agglutination assay, which is a laboratory technique that involves the clumping of particles in the presence of the antigen. This test is primarily conducted on urine samples to identify whether BTA is present. However, it is important to note that a positive result for BTA does not confirm the presence of a bladder tumor, as other medical conditions—such as renal stones, nephritis, renal cancer, urinary tract infections, cystitis, or recent trauma to the bladder or kidneys—can also lead to elevated levels of this antigen. Therefore, a positive BTA test necessitates further diagnostic evaluations to accurately determine the presence of a bladder tumor.
© Copyright 2026 Coding Ahead. All rights reserved.
The immunoassay for tumor antigen, specifically the bladder tumor antigen (BTA), is indicated for the following conditions:
The procedure for conducting the immunoassay for tumor antigen involves several key steps:
After the immunoassay for tumor antigen is completed, the patient may not require any specific post-procedure care, as the test is non-invasive and involves only urine collection. However, it is crucial for healthcare providers to discuss the results with the patient. If the test result is positive for bladder tumor antigen, further diagnostic testing, such as imaging studies or cystoscopy, may be recommended to confirm the presence of a bladder tumor and to evaluate the patient's condition comprehensively. Additionally, patients should be informed about the potential for false-positive results due to other medical conditions, emphasizing the importance of follow-up evaluations.
| Short Descr | IMMUNOASSAY TUMOR QUAL | Medium Descr | IMMUNOASSAY TUMOR ANTIGEN QUAL/SEMIQUANTITATIVE | Long Descr | Immunoassay for tumor antigen, qualitative or semiquantitative (eg, bladder tumor antigen) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | Yes | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 235 - Other Laboratory |
| QW | Clia waived test | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GZ | Item or service expected to be denied as not reasonable and necessary |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Medium description changed. Short description changed. |
| 2001-01-01 | Added | First appearance in code book in 2001. |
Get instant expert-level medical coding assistance.